Brain-derived neurotrophic factor serum levels and genotype: Association with depression during interferon-α treatment

Neuropsychopharmacology

Volumn 38, Issue 6, 2013, Pages 985-995

  Lotrich, Francis E ^a   Albusaysi, Salwa ^b   Ferrell, Robert E ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

cytokine; growth factor; inflammation; major depression; pharmacogenetic; psychoneuroimmunology

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN TRANSPORTER;

ADULT; AGED; ALLELE; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; COMPARATIVE STUDY; DECREASED APPETITE; DEPRESSION; FATIGUE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; SUICIDAL IDEATION; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COHORT STUDIES; DEPRESSION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NEURAL PATHWAYS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876543050     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.263     Document Type: Article

References (129)

1. Aguilera M, Arias B, Wichers M, Barrantes-Vidal N, Moya J, Villa H et al (2009). Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med 39: 1425-1432.
2. Anisman H (2009). Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 34: 4-20.
3. Aydemir C, Yalcin ES, Aksaray S, Kisa C, Yildirim SG, Uzbay T et al (2006). Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Progr Neuropsychopharmacol Biol Psychiatry 30: 1256-1260.
4. Barrientos RM, Sprunger DB, Campeau S, Higgins EA, Watkins LR, Rudy JW et al (2003). Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 121: 847-853.
5. Beck A, Steer R, Garbin M (1988). Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psych Rev 8: 77-100.
6. Beevers CG, Wells TT, McGeary JE (2009). The BDNF Val66Met polymorphism is associated with rumination in healthy adults. Emotion 9: 579-584.
7. Ben Menachem-Zidon O, Goshen I, Kreisel T, Ben Menahem T, Reinhartz E, Ben Hur T et al (2008). Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolationinduced impairment in memory and neurogenesis. Neuropsychopharmacology 33: 2251-2262.
8. Besser M, Wank R (1999). Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162: 6303-6306.
9. Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, Abate M, Segala M, Giacopuzzi M et al (2006). Electroconvulsive therapy (ECT) increases serum brain derived neurotrophic factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol 16: 620-624.
10. Borroni B, Grassi M, Archetti S, Costanzi C, Bianchi M, Caim L et al (2009). BDNF genetic variations increase the risk of Alzheimer's disease-related depression. J Alzheimers Dis 8: 867-875.
11. Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C et al (2008). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Mol Psychiatry 14: 1095-1104.
12. Calabrese F, Molteni R, Racagni G, Riva MA (2009). Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 34(Suppl 1): S208-S216
13. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB et al (2002). Neurobehavioral effects of interferon-a in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26: 643-652.
14. Castren E, Rantamaki T (2010). The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 70: 289-297.
15. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M (2009). Reduced peripheral brainderived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol 13: 103-108.
16. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50: 260-265.
17. Chen L, Lawlor DA, Lewis SJ, Yuan W, Abdollahi MR, Timpson NJ et al (2008). Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 147B: 814-821.
18. Choi S-W, GBhang S, Ahn J-H (2011). Diurnal variation and gender differences of plasma brain-derived neurotrophic factor in healthy human subjects. Psychiatry Res 186: 427-430.
19. Cirulli F, Reif A, Herterich S, Lesch KP, Berry A, Francia N et al (2011). A novel BDNF polymorphism affects plasma protein levels in interaction with early adversity in rhesus macaques. Psychoneuroendocrinology 36: 382-379.
20. Cortese GP, Barrientos RM, Maier SF, Patterson SL (2011). Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes. J Neurosci 31: 4274-4279.
21. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9: 46-56.
22. Drachmann BJ, Bock C, Vinberg M, Werg eT, Gether U, Vedel Kessing L (2009). Interaction between genetic polymorphisms and stressful life events in first episode depression. J Affect Disorder 119: 107-115.
23. Duman CH, Schlesinger L, Kodama M, Russel DS, Duman RS (2007). A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 61: 661-670.
24. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116-1127.
25. Duncan LE, Hutchison KE, Carey G, Craighead WE (2009). Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. J Affect Disorder 115: 215-219.
26. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269.
27. Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR et al (2005). Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 58: 175-189.
28. Fahey B, Hickey B, Kelleher D, O'Dwyer AM, O'Mara SM (2007). The widely-used anti-viral drug interferon-alpha induces depressive-and anxiogenic-like effects in healthy rats. Behav Brain Res 182: 80-87.
29. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM et al (2007). Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 62: 1324-1333.
30. Felger JC, Alagbe O, Pace TWW, Woolwine BJ, Hu F, Raison CL et al (2011). Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun 25: 1094-1098.
31. Figueira P, Malloy-Diniz L, Campos SB, Miranda DM, Romano-Silva MA, De Marco L et al (2010). An association study between the Val66Met polymorphism of the BDNF gene and postpartum depression. Arch Womens Ment Health 13: 285-289.
32. Foley DL, Neale MC, Gardner CO, Pickles A,SKK (2003). Major depression and associated impairment: same or different genetic and environmental risk factors? Am J Psychiatry 160: 2128-2133.
33. Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE (2009). Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. J Psychiatr Res 177: 240-245.
34. Furuno T, Nakanishi M (2006). Neurotrophic factors increase tumor necrosis factor-alpha-induced nuclear translocation of NF-kappaB in rat PC12 cells. Neurosci Letters 392: 240-244.
35. Gass P, Hellweg R (2010). Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker for affective disorders? Int J Neuropsychopharmacol 13: 1-4.
36. Gatt JM, Kuan SA, Dobson-Stone C, Paul RH, Joffe RT, Kemp AH et al (2008). Association between BDNF Val66Met polymorphism and trait depression is mediated via resting EEG alpha band activity. Biol Psychology 79: 275-284.
37. Gatt JM, Nemeroff CB, Schofield PR, Paul RH, Clark CR, Gordon E et al (2010). Early life stress combined with serotonin 3A receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. Biol Psychiatry 68: 818-824.
38. Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G et al (2005). Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 51: 234-238.
39. Goldstein B, Collinger KA, Lotrich FE, Marsland AL, Gill M-K, Axelson DA et al (2011). Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol 1: 479-484.
40. Guan Z, Fang J (2006). Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav Immun 20: 64-71.
41. Haroon E, Raison CL, Miller AH (2012). Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37: 137-162.
42. Hashimoto K (2010). Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64: 341-357.
43. Hayden EP, Klein DN, Dougherty LR, Olino TM, Dyson MW, Durbin CE et al (2010). The role of brain-derived neurotrophic factor genotype, parental depression, and relationship discord in predicting early-emerging negative emotionality. Psychol Sci 21: 1678-1685.
44. Henderson ND, Turri MG, DeFries JC, Flint J (2004). QTL analysis of multiple behavioral measures of anxiety in mice. Behav Genet 34: 267-293.
45. Jang KL, Livesley WJ, Taylor S, Stein MB, Moon EC (2004). Heritability of individual depressive symptoms. J Affect Disord 80: 125-133.
46. Jen JF, Glue P, Ezzet F, Chung C, Gupta SK, Jacobs S et al (2001). Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther 69: 407-421.
47. Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF et al (2005). BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30: 1353-1361.
48. Kairisalo M, Korhonen L, Sepp M, Pruunsild P, Kukkonen JP, Kivinen J et al (2009). NF-kappaB-dependent regulation of brain-derived neurotrophic factor in hippocampal neurons by X-linked inhibitor of apoptosis protein. Eur J Neurosci 30: 958-966.
49. Kaneko N, Kudo K, Mabuchi T, Takemoto K, Fujimaki K, Wati H et al (2006). Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 1: 2619-2626.
50. Kanellopoulos D, Gunning FM, Morimoto SS, Hoptman MJ, Murphy CF, Kelly RE et al (2011). Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 19: 13-22.
51. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HWM et al (2010). Depressive symptoms following interferon-a therapy: mediated by immune-induced reductions in brainderived neurotrophic factor? Int J Neuropsychopharmacol 14: 247-253.
52. Kerschensteiner M, Gallmeier E, Behrens L, Leal V, Misgeld T, Klinkert WE et al (1999). Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189: 865-870.
53. Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Kim YH et al (2008). BDNF genotype potentially modifying the association between incident stroke and depression. Neurobiol Aging 29: 789-792.
54. Kimata H (2005). Brain-derived neurotrophic factor selectively enhances allergen-specific IgE production. Neuropeptides 39: 379-383.
55. Koo JW, Duman RS (2008). IL-1beta is an essential mediator of the antineurogenic and anhedondic effects of stress. PNAS 105: 751-756.
56. Koo JW, Russo SJ, Ferguson D, Nestler NJ, Duman RS (2010). Nuclear factor-kb is a critical mediator of stress-impaired neurogenesis and depressive behavior. PNAS 107: 2669-2674.
57. Kraus MR, Al-Taie O, Schefer A, Pfersdorff M, Lesch KP, Scheurlen M (2007). Serotonin-1A receptor gene (HTR1A) vairation predicts interferon-induced depression chronic hepatitis C. Gastroenterology 132: 1279-1286.
58. Kunugi H, Hor iH, Adachi N, Numakawa T (2010). Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 64: 477-459.
59. Kunz D, Walker G, Bedoucha M, Certa U, Marz-Weiss P, Dimitriades-Schmutz B et al (2009). Expression profiling and ingenuity biological function analyses of interleukin-6-versus nerve growth factor-stimulated PC12 cells. BMC Genomics 10: 90
60. Lau JY, Goldman D, Buzas B, Hodgkinson C, Leibenluft E, Nelson E et al (2010). BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to emotional faces in anxious and depressed adolescents. Neuroimage 53: 952-961.
61. Lavebratt C, Aberg E, Sjoholm LK, Forsell Y (2010). Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 125: 249-255.
62. Liguori M, Fera F, Patitucci A, Manna I, Condino F, Valentino P et al (2009). A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsingremitting multiple sclerosis. Brain Res 1256: 123-128.
63. Lisak RP, Benjamins J, Bealmear B, Nedelkoska L, Yao B, Land S et al (2007). Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation 4: 30
64. Lotrich FE (2009). Risk factors and prevention of interferoninduced depression. Dialogues Clin Neurosci 11: 417-426.
65. Lotrich FE (2011). Gene-environment interactions in geriatric depression. Psychiatr Clin North Am 34: 357-376.
66. Lotrich FE (2012). Inflammatory cytokines, growth factors, and depression. Curr Pharm Des 18: 5920-5935.
67. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG (2009). Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 65: 344-348.
68. Lotrich FE, Ferrell RF, Rabinovitz M, Pollock BG (2010). Labile anger during interferon-alpha treatment is associated with a polymorphism in tumor necrosis factor-alpha. Clin Neuropharmacol 33: 191-197.
69. Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P (2011). IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res 31: 331-336.
70. Lotrich FE, Pollock BG, Kirshner M, Ferrell RF, Reynolds CR (2008). Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response. J Psychiatry Neurosci 33: 123-130.
71. Lotrich FE, Rabinovitz F, Gironda P, Pollock BG (2007). Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosomat Res 63: 131-135.
72. Lotrich FE, Sears B, McNamara R (2012). Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: relationship with interleukin-6. Brain Behav Immun epub ahead of print doi:10.1016/j.bbi.2012.08.007.
73. Maes M (2011). Depression is an inflammatory disease, but cellmediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 664-675.
74. McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH et al (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 31: 180-186.
75. Middeldorp CM, Slof-Op 't Landt MC, Medland SE, van Beijsterveldt CE, Bartels M, Willemsen G et al (2010). Anxiety and depression in children and adults: influence of serotonergic and neurotrophic genes? Genes Brain Behav 9: 808-816.
76. Miller AH, Maletic V, Raison CL (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65: 732-741.
77. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH et al (1992). Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41: 237-248.
78. Montag C, Basten U, Stelzel C, Fiebach CJ, Reuter M (2010). The BDNF Val66Met polymorphism and anxiety: support for animal knock-in studies from a genetic association study in humans. Psychiatry Res 79: 86-90.
79. Montag C, Reuter M, Newport B, Elger C, Weber B (2008). The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. Neuroimage 42: 1554-1559.
80. Montag C, Weber B, Fliessbach K, Elger C, Reuter M (2009). The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression. Psycholog Med 39: 1831-1839.
81. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
82. Morrow GR, Hickock JT, Roscoe JA, Raubertas RF, Andrews PL, Flynn PJ et al (2003). Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the Univeristy of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 21: 4635-4641.
83. Mossner R, Daniel S, Albert D, Heils A, Okladnova O, Schmitt A et al (2000). Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 36: 197-202.
84. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP (1998). Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 33: 251-254.
85. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370: 851-858.
86. Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi J, Tandon NN et al (2000). Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 470: 113-117.
87. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR et al (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk for relapse: a STAR D report. Psychol Med 0: 41-50.
88. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H (2010). BDNF function and intracellular signaling in neurons. Histol Histopathol 25: 237-258.
89. Ozan E, Okur H, Eker C, Eker OD, Gonul AS, Akarsu N (2010). The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels. Brain Res Bull 1: 61-65.
90. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37: 1553-1561.
91. Peng CH, Chiou SH, Chen SJ, Chou YC, Ky HH, Cheng CK (2008). Neuroprotection by imipramine against lipopolysaccharideinduced apoptosis in hippocampus-dreived neural stem cellsmediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol 18: 128-140.
92. Poduslo JF, Curran GL (1996). Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 36: 280-286.
93. Porcelli S, Fabbri C, Serretti A (2012). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22: 239-258.
94. Prakash YS, Thompson MA, Pabelick CM (2009). Brain-derived neurotrophic factor in TNF-alpha modulation of Ca2 in human airway smooth muscle. Am J Respir Cell Mol Biol 41: 603-611.
95. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE (2009). Cytokine-induced depression during IFN-a treatment: the role of IL-6 and sleep quality. Brain Behav Immun 23: 1109-1116.
96. Pregelj P, Nedic G, Paska AV, Zupanc T, Nikolac M, Balazic J et al (2011). The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J Affect Disord 128: 287-290.
97. Quan N, Banks WA (2007). Brain-immune communication pathways. Brain Behav Immun 21: 727-735.
98. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ et al (2009). Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 65: 296-303.
99. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH (2008). Interferon-[alpha] effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 15: 535-547.
100. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt GJ, Miller AH (2010a). Interferon-alpha effects on diurnal hypothalamicpituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 15: 535-547.
101. Raison CL, Capuron L, Miller AH (2006). Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31.
102. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt GJ et al (2010b). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393-403.
103. Raison CL, Demetrashvili M, Capuron L, Miller AH (2005). Neuropsychiatric adverse effects of interferon-a: recognition and management. CNS Drugs 19: 105-123.
104. Rezaee F, Rellick SL, Piedimonte G, Akers SM, O'Leary HA, Martin K et al (2010). Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway. PLoS ONE 5: e9690
105. Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P et al (2007). The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport 18: 1291-1293.
106. Roth TL, Lubin FD, Funk AJ, Sweatt JD (2009). Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry 65: 760-769.
107. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al (2003). Activation of the trkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23: 349-357.
108. Sarchiapone M, Carli V, Roy A, Iacoviello L, Cuomo C, Latella M et al (2008). Association of polymorphism (Val66Met) of brainderived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiol 57: 139-145.
109. Sartorius A, Hellweg R, Litzke J, Vogt M, Dormann C, Vollmayr B et al (2009). Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 42: 270-276.
110. Schule C, Zill P, Baghai TC, Eser D, Zwanzger P, Wenig N et al (2006). Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology 31: 1019-1025.
111. Sen S, Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64: 527-532.
112. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C et al (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54: 70-75.
113. Su K-P, Huang S-Y, Peng C-Y, Lai H-C, Huang C-L, CHen Y-C et al (2010). Phospholipase A2 and cycloxygenase 2 genes influence the risk of interferon-a-induced depression by regulating polyunsaturated faty acids levels. Biol Psychiatry 67: 550-557.
114. Su N, Zhang L, Fei F, Hu H, Wang K, Hui H et al (2011). The brainderived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res 1415: 119-126.
115. Suchanek R, Owczarek A, Kowalczyk M, Kucia K, Kowalski J (2011). Association between C-281A and val66met functional polymorphisms of BDNF gene and risk of recurrent major depressive disorder in Polish population. J Mol Neurosci 43: 524-530.
116. Targum SD, Fava M (2011). Fatigue as a residual symptom of depression. Innov Clin Neurosci 8: 1040-1043.
117. Taylor WD, McQuoid DR, Ashley-Koch A, MacFall JR, Bridgers J, Krishnan RR et al (2011). BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenom J 11: 146-154.
118. Terracciano A, Martin B, Ansari D, Tanaka T, Ferrucci L, Maudsley S et al (2010). Plasma BDNF concentration, Val66Met genetic variant and depression-related personality traits. Genes Brain Behav 9: 512-218.
119. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW (2008). Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 29: 1380-1393.
120. Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar S, Knudsen GM (2007). Measurements of brain-derived neurotrophic factor: Methodological aspects and demographical data. Brain Res Bull 73: 143-149.
121. Tsao C-W, Lin Y-S, Cheng J-T, Lin C-F, Wu H-T, Wu S-R et al (2008). Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 22: 753-760.
122. Verhagen M, van der Meij A, van Deurzen P, Janzing JG, Arias-Vasquez A, Buitelaar JK et al (2010). Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 15: 260-271.
123. Wray NR, James MR, Handoko HY, Dumenil T, Lind PA, Montgomery GW et al (2008). Association study of candidate variants from brain-derived neurotrophic factor and dystrobrevin-binding protein 1 with neuroticism, anxiety, and depression. Psychiatr Genet 18: 219-225.
124. Zhang L, Fang Y, Zeng Z, Lian Y, Wei J, Zhu H et al (2011). BDNF gene polymorphisms are associated with Alzheimer's diseaserelated depression and antidepressant response. J Alzheimers Dis 26: 523-530.
125. Zhou Z, Lu T, Xu G, Yue X, Zhu W, Ma M et al (2011). Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism. Clin Chem Lab Med 49: 185-189.
126. Zhu C-B, Blakely RD, Hewlett WA (2006). The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31: 2121-2131.
127. Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA (2010). Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 35: 2510-2520.
128. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R (2002). Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125: 2381-2391.
129. Zigmond AS, Snaith RP (1983). The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67: 361-370.